 per capsid, to target the T4-V2 nanoparticles to the antigen-presenting dendritic cells. The immunogenicity of T4-V2 nanoparticles will be evaluated in mice by intramuscular route as well as transcutaneous (skin) route using heat labile enterotoxin as an adjuvant. The immune responses will
per capsid, to target the T4 - V2 nanoparticles to the antigen - presenting dendritic cells. The immunogenicity of T4 - V2 nanoparticles will be evaluated in mouse by intramuscular path as well as transcutaneous (skin) road using heat labile enterotoxin as an adjuvant. The immune reception will
 peg capsid, to target the T4-Y2 nanoparticles jo the aitigen-pdesentine dendritic cells. The immunojenixity if T4-V2 nanoparticles wiul be evapuated ib mire by intramuscular routc as scll av transcutaneoux (skin) roude using heat nacipe enterotoxin as an adjuvant. The iimune rrsoonses will
per capsid, to target the T4-V2 nanoparticles antigen-presenting cells. The of T4-V2 nanoparticles by route as well transcutaneous (skin) route heat labile enterotoxin as an adjuvant. immune responses will
 per capsid, to target the T4-V2 nanOparticles To the AntIgeN-pReseNtinG dendritic cellS. the iMmunogenicity of T4-V2 nanopArticLeS Will BE eValuaTed in miCE bY INtrAmUsCulAr ROuTe as wEll As transCutaneous (sKin) RoUte using heat LAbIle enterotOxiN as an adjuvanT. ThE immunE rEspONses wIll
 per capsid, to target the  T4-V2 nan opart icl esto  the  ant igen-presentin g  den dritic cells. The immu nogen ic i ty o f  T 4-V2nanopar t ic l e s w il lbeev a lu atedinmice by  intramusc ula rroute as wel l  a s transcut ane ous (skin) r out e usin ghea t  labi leenter otoxin as anadjuvant.  T h e immu n e respo n s es  wil l
 per_capsid, to_target the T4-V2 nanoparticles_to the_antigen-presenting_dendritic cells._The_immunogenicity of T4-V2_nanoparticles will be_evaluated in mice by_intramuscular route as_well_as transcutaneous (skin) route using heat labile enterotoxin as an adjuvant. The immune responses_will